Currency In USD
| Previous Close | 1.29 |
| Open | 1.36 |
| Day High | 1.48 |
| Day Low | 1.35 |
| 52-Week High | 12.8 |
| 52-Week Low | 0.62 |
| Volume | 570,614 |
| Average Volume | 172,585 |
| Market Cap | 3.02M |
| PE | -0.26 |
| EPS | -5.57 |
| Moving Average 50 Days | 0.88 |
| Moving Average 200 Days | 3.52 |
| Change | 0.15 |
FibroBiologics Completes Site Onboarding for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers
GlobeNewswire Inc.
Mar 05, 2026 1:30 PM GMT
HOUSTON, March 05, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for
FibroBiologics, Inc. Announces Issuance of U.S. Patent Covering Fibroblast Cell Therapy for the Treatment of Osteoporosis
GlobeNewswire Inc.
Mar 02, 2026 1:30 PM GMT
HOUSTON, March 02, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and pot
FibroBiologics to Present at the BIO Investment & Growth Summit
GlobeNewswire Inc.
Feb 26, 2026 1:30 PM GMT
HOUSTON, Feb. 26, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for c